Progressive pulmonary fibrosis treatment strategy

Progressive Pulmonary Fibrosis, PPF is a chronic, active pulmonary disease characterized by adhesive protein deposition and fibrosis in the pulmonary tissue, leading to the destruction of the lung structure and a decrease in function. The following is a detailed description of its treatment strategy: All-body symptoms such as loss of weight and appetite may be associated. Auxiliary examination of chest image: e.g. high resolution CT (HRCT) is an important means of diagnosing lung fibrosis. PPF can be seen on the HRCT as a double-pulmonary epidemiology, e.g. a mesh image, a change in beehive sample, and tortilla bronchial extension. Pulmonary function examination: For example, a strong lung activity (FVC) and carbon monoxide (DLCO) can be used to assess the extent of damage to the lung function. PPF patients usually show an absolute decline in FVC and DLCO. Serobiology: An increase in the level of biomarkers such as salinized sugar chain antigens (KL-6) may indicate the presence of pulmonary fibrosis. Organization of pathology examinations: A pathological examination of tissue samples obtained through pulmonary activity examinations is the gold standard for the diagnosis of pulmonary fibrosis. Pulmonary biopsy, however, is a creative examination, which must be determined on a trade-off basis. The diagnostic criteria are based on guidelines from the American Breast Science Society, the European Respiratory Society, etc., and PPF diagnosis is usually based on the following criteria: there has been a deterioration of respiratory symptoms in the past year and the physiological evidence accompanying the progression of the disease (e.g. a 5 per cent drop in the FVC absolute value or a 10 per cent decline in the DLCO absolute value) and/or radiological evidence (e.g. an increase in the scope or severity of towed bronchial and fine bronchial expansion, or the emergence of new glass-mixed towed bronchial extension). Treatment of anti-fibrosis drugs: e.g., théfneone and Nidanib, both of which have been shown to slow the progress of specific pulmonary fibrosis (IPF). For PPF patients, the use of these drugs may also be considered to delay the development of the situation. Attention, however, needs to be paid to the side effects of drugs and taboos. Sugar cortex hormones and immunosuppressants: For certain PPF patients, especially those associated with their own immuno- and inflammatory diseases, sugar cortex hormones (e.g., Ponithon) and immunosuppressants (e.g., cyclophosphate, sulfur) may help to reduce the level of pneumonia and fibrosis. However, long-term use requires attention to the side effects and dependence of drugs. Non-pharmaceutical pulmonary rehabilitation treatments, including respiratory, aerobics, etc., are aimed at improving the patient ‘ s resilience and quality of life in the lung. Pulmonary rehabilitation requires individualization of programmes and adaptation to the specific circumstances of the patient. Oxygen: For PPF patients with hypooxins, long-term home Oxygen treatment helps improve quality of life and preparation. The flow and duration of Oxygen treatment needs to be adapted to the patient ‘ s specific circumstances. The operation may be considered for a pulmonary transplant for a PPF patient whose condition is severe, whose medication is ineffective and eligible. Pulmonary transplants can replace damaged lungs and restore the patient ‘ s lung function and quality of life. However, pulmonary transplant surgery is risky and expensive and requires long-term immunosuppressants to prevent exclusion. Lifestyle interventions to stop smoking and to avoid exposure to harmful particles and gases are important measures to prevent PPFs. Nutritionally balanced diets, with more foods with antioxidants, such as vegetables, fruit, etc., help to reduce pneumonia and oxidizing stress. Maintaining the comfort of the mood, avoiding overwork and stress can help to slow down progress. Regular follow-up and monitoring of PPF patients requires periodic supplementary examinations of chest image, lung function, seroscopy etc. to assess the progress of the condition and the effectiveness of treatment. The frequency of follow-up visits and specific projects need to be adjusted to the patient ‘ s condition and the doctor ‘ s advice. The monitoring of drug side effects requires close monitoring of both the side effects and the adverse effects of drugs during drug treatment. In the case of serious side effects or adverse effects, a timely stoppage and medical treatment are required. In the light of the above, the progressive pulmonary fibrosis treatment strategy needs to take into account the clinical performance of the patient, the results of supplementary examinations and the individual situation. Through a standardized diagnostic process and individualized treatment programmes, progress can be delayed, symptoms reduced and the quality of life improved. At the same time, patients are required to actively cooperate with the doctor ‘ s recommendations for treatment, and to conduct regular follow-up and management.